StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
CTEV

Claritev Corporation

CTEV NYSE Services-Business Services, NEC EDGAR ↗
$21.64
-0.83 -3.69%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$367M
Revenue (TTM) ⓘ
$995M
Net income (TTM) ⓘ
-$283M
EPS (TTM) ⓘ
$-17.01
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
-$12.3M
Cash ⓘ
$14.4M
Total assets ⓘ
$4.76B
Gross margin ⓘ
—
52-week range ⓘ
$11.50 – $73.68

AI briefing

from the latest 10-K, 10-Q and 8-K events

Claritev Corp is a healthcare technology, data, and insights company focused on claims cost management and payment integrity.

What they do

Claritev provides out-of-network cost management and in-network payment integrity solutions, using data, analytics, and AI to improve healthcare pricing and billing accuracy. The company processes claims pre-payment, integrating deeply with client technology environments. Its services target wasteful healthcare spending, including billing errors, fraud, and pricing above fair market value.

Revenue drivers

  • Out-of-network cost management — Largest segment, addressing the $10.0 billion TAM for out-of-network services, providing transparency and pricing solutions.
  • In-network payment integrity — Addresses the $3.0 billion TAM for in-network solutions, ensuring billing and payment accuracy.
  • Key client concentration — Two largest clients accounted for approximately 29.2% and 10.4% of 2025 revenues, indicating high dependence on a core group.
  • New markets: payer risk analytics and network transparency — Expanding into adjacent markets representing an estimated $17.0 billion TAM, offering analytic services to payers.

Recent performance

Q2 2026 revenues were $257.5 million, up 6.6% year-over-year, with a net loss of $59.2 million (improved from a $62.6 million loss in Q2 2025). Adjusted EBITDA was $155.8 million, up 1.1% year-over-year, with a margin of 60.5%. For the first half of 2026, revenues totaled $502.2 million, up from $472.9 million in the prior-year period, and net loss was $132.8 million. The company reported operating cash flow of $92.7 million in Q2 2026 and ended with $14.4 million in unrestricted cash.

Strategy

Claritev is one year into a transformation program focused on a broader portfolio of solutions, expanded vertical sales markets, and increased use of AI for operational and innovation leverage. Management highlights strong bookings, with over $70 million in the first half of 2026, aiming for a full-year target of $100 million, which would represent 50% growth over 2025. The company is investing heavily in software development, with over $500 million in cumulative capitalized software over the past five years, to enhance its data and technology platform. The strategy includes developing and acquiring new products to expand into adjacent markets and drive long-term growth.

Risks

  • Key client concentration — A significant client termination or reduction could materially impact revenue; the two largest clients accounted for ~29.2% and ~10.4% of 2025 revenue, and contracts allow termination with relatively short notice.
  • High leverage and liquidity — Long-term debt of $4.64 billion against negative shareholder equity and only $14.4 million in cash, creating refinancing and liquidity risk.
  • Pricing pressure and volume reductions — Past clients have reduced product usage and negotiated lower pricing, which has adversely impacted revenue.
  • Cybersecurity and data breaches — Interruptions or security breaches of IT systems could disrupt operations and harm client relationships.

Outlook

Management updated full-year 2026 guidance, raising revenue to $1.0-1.02 billion (from $985 million to $1 billion) and Adjusted EBITDA to $610-620 million (from $605-615 million). Free cash flow guidance was improved to $5-15 million, with capital expenditures unchanged at $160-170 million. The company expects to achieve its $100 million bookings target, which would be 50% growth over 2025.

Recent SEC filings

40 most recent
Annual, quarterly & current reports